KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Gross Margin (2016 - 2026)

Biocryst Pharmaceuticals filings provide 15 years of Gross Margin readings, the most recent being 1244.92% for Q4 2025.

  • On a quarterly basis, Gross Margin fell 134028.0% to 1244.92% in Q4 2025 year-over-year; TTM through Dec 2025 was 95.93%, a 135.0% decrease, with the full-year FY2025 number at 97.82%, up 54.0% from a year prior.
  • Gross Margin hit 1244.92% in Q4 2025 for Biocryst Pharmaceuticals, down from 98.63% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 99.62% in Q2 2022 to a low of 1244.92% in Q4 2025.
  • Median Gross Margin over the past 5 years was 98.5% (2024), compared with a mean of 29.53%.
  • Biggest five-year swings in Gross Margin: soared 3060bps in 2022 and later crashed -134028bps in 2025.
  • Biocryst Pharmaceuticals' Gross Margin stood at 99.11% in 2021, then decreased by -2bps to 97.0% in 2022, then increased by 1bps to 98.33% in 2023, then fell by -3bps to 95.37% in 2024, then plummeted by -1405bps to 1244.92% in 2025.
  • The last three reported values for Gross Margin were 1244.92% (Q4 2025), 98.63% (Q3 2025), and 98.29% (Q2 2025) per Business Quant data.